Anthracycline Antibiotics in Cancer Therapy: Proceedings of the International Symposium on Anthracycline Antibiotics in Cancer Therapy, New York, New York, 16–18 September 1981: Developments in Oncology, cartea 10
Editat de Franco M. Muggia, Charles W. Young, Stephen K. Carteren Limba Engleză Paperback – 20 mar 2012
Din seria Developments in Oncology
- 5% Preț: 360.70 lei
- 5% Preț: 345.71 lei
- 5% Preț: 1096.98 lei
- 5% Preț: 360.86 lei
- 5% Preț: 1125.88 lei
- 5% Preț: 3183.63 lei
- 5% Preț: 371.30 lei
- 5% Preț: 374.57 lei
- 5% Preț: 1417.91 lei
- 5% Preț: 375.34 lei
- 5% Preț: 368.57 lei
- 5% Preț: 1102.10 lei
- 5% Preț: 368.37 lei
- 15% Preț: 604.56 lei
- 5% Preț: 1425.76 lei
- 5% Preț: 1119.10 lei
- 5% Preț: 374.57 lei
- 5% Preț: 1416.09 lei
- 5% Preț: 723.21 lei
- 5% Preț: 713.33 lei
- 5% Preț: 1424.16 lei
- 5% Preț: 718.65 lei
- 5% Preț: 367.64 lei
- 5% Preț: 1423.22 lei
- 5% Preț: 1097.71 lei
- 5% Preț: 3836.15 lei
- 5% Preț: 1100.64 lei
- 5% Preț: 1109.08 lei
- 5% Preț: 1419.39 lei
- 5% Preț: 1439.31 lei
- 5% Preț: 1114.71 lei
Preț: 384.80 lei
Preț vechi: 405.06 lei
-5% Nou
Puncte Express: 577
Preț estimativ în valută:
73.64€ • 76.41$ • 61.55£
73.64€ • 76.41$ • 61.55£
Carte tipărită la comandă
Livrare economică 15-29 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9789400976320
ISBN-10: 9400976321
Pagini: 592
Ilustrații: 568 p.
Dimensiuni: 155 x 235 x 31 mm
Greutate: 0.82 kg
Ediția:Softcover reprint of the original 1st ed. 1982
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Oncology
Locul publicării:Dordrecht, Netherlands
ISBN-10: 9400976321
Pagini: 592
Ilustrații: 568 p.
Dimensiuni: 155 x 235 x 31 mm
Greutate: 0.82 kg
Ediția:Softcover reprint of the original 1st ed. 1982
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Developments in Oncology
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
Section 1. Biolgical Effects.- Antitumor Activity of Anthracyclines: Experimental Studies.- Anthracycline Antitumor Antibiotics: Their Carcinogenicity and their Mutagenicity.- The Immunological Activity of Anthracyclines.- Section 2. Mechanism of Action.- Doxorubicin and Related Compounds. I. Physiochemical Characterization of the DNA Complex.- Consequences of DNA Intercalation: Protein-Associated DNA Strand Breaks.- Free Radical Damage.- Intracellular, Intranuclear, and Subchromosomal Localization of Anthracycline Antibiotics.- Effects of Anthracyclines on Macromolecules and their Syntheses.- Biotransformations of Anthracyclines in the Smooth Endoplasmic Reticulum of Rat Liver.- Transport and Storage of Anthracyclines in Experimental Systems and Human Leukemia.- Calcium Flux and Metabolism in the Pigeon Heart Following Doxorubicin Treatment: A Study of Acute Changes.- The Role of Acute Lipid Peroxidation in Doxorubicin Cardiotoxicity.- The Physicochemical Properties and Transmembraneous Transport of Doxorubicin.- Section 3. Drug Development.- Doxorubicin and Related Compounds. II. Structure-Activity Considerations.- Second-Generation Anthracyclines.- Factors in Selection of New Anthracyclines.- Implications of Free Radical Activation for Improved Anthracycline Therapy.- Screening for Second Generation Anthracyclines in a Human Tumor Cloning System.- Activity of Anthracyclines on Human Tumors in Vitro.- Pharmacologic and Therapeutic Characteristics of Anthracycline Liposome Preparation.- N-L-Leucyl Derivatives of Anthracyclines: Toxic and Chemotherapeutic Properties.- Alternative Methods of Drug Delivery.- Section 4. Cardiotoxicity.- The Role of Free Radical Damage in the Genesis of Doxorubicin Cardiac Toxicity.- Screening for Cardiotoxic Properties.- Role of Oxygen Radical Formation in Anthracycline Cardiac Toxicity.- Morphologic Assessment of Cardiac Lesions Caused by Anthracyclines.- Cardiac Monitoring of Patients Receiving Anthracyclines.- Reduction of Adriamycin Cardiac Toxicity by Schedule Manipulation.- Rationale and Design of a Trial to Evaluate the Cardiotoxicity of Weekly Schedules of Adriamycin, with Endomyocardial Biopsy Used as an End Point.- Anthracyclines in Cancer Chemotherapy.- Section 5. Doxorubicin: New Clinical Investigations.- Doxorubicin in the 1980s: Is there still Room for Clinical Investigation?.- A Phase I/II Study of 6-Hour and 24-Hour Intravenous Infusions of Doxorubicin.- Intravesical Chemotherapy in the Treatment and Prophylaxis of Bladder Tumors, with Special Reference to Doxorubicin.- Intraperitoneal Adriamycin in Ovarian Cancer.- Role of Adriamycin in Breast Cancer and Sarcomas.- Prospects for Doxorubicin in Adjuvant Breast Cancer Trials.- Clinical Evaluation of 4?-Epi Doxorubicin and 4-Demethoxy Daunorubicin.- Section 6. Clinical Studies with new Anthracyclines and Related Compounds.- The Anthracyclines--A Historical Perspective.- Phase-I Trial with 4-Demethoxydaunorubicin.- Clinical Studies of New Anthracycline Analogs.- A Clinical Overview of Aclacinomycin A in Japan.- The Clinical Pharmacology of Aclacinomycin-A.- Phase II Evaluation of N-Trifluoroacetyladriamycin-14-Valerate (AD 32).- Preliminary Experience with Marcellomycin: Preclinical and Clinical Aspects.- Preliminary Phase II Experience with 4?Epidoxorubicin.